Recombinant Human Myosin-9 (MYH9), partial

^{In
Stock}

中文名稱：

人MYH9重組蛋白
品名簡稱：

Recombinant Human MYH9 protein, partial
貨號：

CSB-EP015303HUe0
說明書：

MSDS Datasheet
規格：

￥1344
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

MYH9
Uniprot No.：

P35579
別名：

BDPLT 6; BDPLT6; Cellular myosin heavy chain; Cellular myosin heavy chain type A; DFNA 17; DFNA17; EPSTS; FTNS; MGC104539; MHA; MYH 2A; MYH 9; MYH2A; MYH9; MYH9_HUMAN; MYHas8; MyHC 2A; MyHC IIa; MyHC2A; MyHCIIa; MYHSA 2; MYHSA2; Myosin 9; Myosin heavy chain 9; Myosin heavy chain 9 non muscle; Myosin heavy chain; Myosin heavy chain non muscle IIa; Myosin heavy chain nonmuscle IIa; Myosin heavy polypeptide 2; Myosin heavy polypeptide 9 non muscle; Myosin-9; Myosin9; NMHC II A; NMMHC A; NMMHC II a; NMMHC II-a; NMMHC IIA; NMMHC-A; NMMHC-IIA; NMMHCA; Non muscle myosin heavy chain A; Non muscle myosin heavy chain; Non muscle myosin heavy chain II A; Non muscle myosin heavy polypeptide 9; non-muscle IIa; Non-muscle myosin heavy chain A; Non-muscle myosin heavy chain IIa; Nonmuscle myosin heavy chain A; Nonmuscle myosin heavy chain II A; type A
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

E.coli
分子量：

54.2kDa
表達區域：

2-241aa
氨基酸序列

AQQAADKYLYVDKNFINNPLAQADWAAKKLVWVPSDKSGFEPASLKEEVGEEAIVELVENGKKVKVNKDDIQKMNPPKFSKVEDMAELTCLNEASVLHNLKERYYSGLIYTYSGLFCVVINPYKNLPIYSEEIVEMYKGKKRHEMPPHIYAITDTAYRSMMQDREDQSILCTGESGAGKTENTKKVIQYLAYVASSHKSKKDQGELERQLLQANPILEAFGNAKTVKNDNSSRFGKFIRI
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

N-terminal GST-tagged
產品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
產品描述：

Recombinant Human Myosin-9/MYH9 produced in E.coli contains 240 amino acids covering the partial-length of MYH9 protein (2-241AA). And it has its N-terminus fused with a GST-tag and a total molecular weight of 54.2 kDa. The purity of this human MYH9 protein is greater than 90% measured by SDS-PAGE. This protein is in-stock, which means there is no waiting period for protein preparation. This recombinant MYH9 protein may find uses in the specific antibody synthesis or the studies of the cell cycle.

MYH9, also called NMM-IIA, is a myosin that exerts a vital role in cell adhesion, migration, proliferation, and differentiation. Acting as a cytokine, MYH9 executes proliferative and progressive effects in cancer by participating in cytoskeletal reorganization, cellular pseudopodia formation, and migration. Additionally, MYH9 is closely associated with the progress and poor prognosis of most solid tumors.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis. Promotes cell motility in conjunction with S100A4. During cell spreading, plays an important role in cytoskeleton reorganization, focal contact formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10.
基因功能參考文獻：
1. These results indicate that nonmuscle myosin heavy chain-IIs interact with sodium channel alpha subunits subunits in an isoform-dependent manner and influence their functional properties. PMID: 29956586
2. In neutrophilic leucocytes from MYH9-related disease patients NMIIa inclusions are accompanied by increased lipid storage in droplets, suggesting that NMIIa dysfunction may contribute to lipid imbalance in man. PMID: 28361956
3. A missense mutation (c.1124C>T:p.S375F) was found in a congenital thrombocytopenia patient and his affected mother. It was associated with abnormal neutrophil NMMHC-IIA localization. PMID: 28293712
4. Our results suggest that MYH9 rs3752462 is significantly associated with an increased risk of diabetic kidney disease in Chinese Han individuals. PMID: 29862302
5. Results suggest that coupling between actin and microtubule cytoskeletons driven by Myosin II and KIF20A ensures the spatial coordination between RAB6-positive vesicles fission from Golgi/trans-Golgi network membranes and their exit along microtubules. PMID: 29093437
6. These results suggest that cytoplasmic multimolecular protein complexes containing myosin-9 and tropomyosin are involved in the regulation of cellular response to LYSOPHOSPHATIDIC ACID. PMID: 30199160
7. miR-647 functions as a tumor metastasis suppressor in gastric cancer by targeting SRF/MYH9 axis. PMID: 28900514
8. MYO18A has the potential to form a multiprotein complex that links the Golgi apparatus to F-actin, which regulates muscle integrity and function during early development PMID: 27824130
9. Report that PTCSC2 binds myosin-9 (MYH9). In a bidirectional promoter shared by FOXE1 and PTCSC2, MYH9 inhibits the promoter activity in both directions. This inhibition can be reversed by PTCSC2, which acts as a suppressor. PMID: 28049826
10. demonstrated that though the targeted integration site for exogenous genes is shifted to MYH9 intron 2 (about 500bp downstream exon 2), the high HR efficiency and the endogenous MYH9 gene integrity are not only preserved, but the expected expression of the inserted gene(s) is observed in a pre-designed set of experiments conducted in mouse ES cells PMID: 29438440
11. These distinct functions of NMIIA and NMIIB might promote intrinsic and directed migration of normal human fibroblasts. PMID: 29486156
12. ALPK1 is a kinase that participates in the regulation of Golgi-derived TNF-alpha trafficking through myosin IIA phosphorylation in the inflammation of gout. PMID: 27169898
13. we present high MYH9 expression as a reliable and powerful prognostic factor for patients with AML. PMID: 27437869
14. Mutations of MYH9 cause MYH9-RD, a form of congenital thrombocytopenia characterized by giant platelets and no platelet functional abnormalities. PMID: 28368695
15. Findings suggest that the tumor suppressor capability of wtp53 is dependent upon functional NMIIA and that the invasive phenotype of high-risk mutp53 is independent of NMIIA. PMID: 28160562
16. Heterozygous deletional mutation (c.5803delG) in exon 41 of the MYH9 gene is associated with inherited thrombocytopenia. PMID: 28604953
17. cytokinesis failure in megakaryocytes is the consequence of both the absence of NMIIB and a low RhoA activity that impairs NMIIA localization at the cleavage furrow through increased actin turnover. PMID: 27737892
18. The loss of junctional NMIIA, upon Coronin 1B knockdown, perturbed RhoA signaling. PMID: 27650961
19. Results identified nonsynonymous variants in MYH9 and ABCA4 to be the most frequent risk loci in nonsyndromic orofacial clefts in the Taiwanese population. PMID: 27527345
20. Our study is the first to identify genetic predisposition to transplant renal artery stenosis in patients with MYH9 risk allelic variants (rs4821480, rs4821481, rs3752462, rs11089788, rs136211, rs5756168, rs2032487, and rs2239784) PMID: 27496447
21. The hearing impairment associated with MYH9 disorder in this family was characterized as adult onset, progressive, and high-frequency dominant. Hematological manifestations of MYH9 disorder show complete penetrance, whereas extra-hematological manifestations show incomplete penetrance and variable expressivity in this family. PMID: 26942920
22. mass spectrum followed by immunoprecipitation identified non-muscle myosin heavy chain-IIA (NMMHC-IIA) as the CXCR4-interacting protein. Furthermore, pharmaceutical inhibition of NMMHC-IIA by blebbistatin dampened the nuclear translocation of CXCR4 as well as the metastatic capacity of RCC cells PMID: 27634189
23. The rs3752462 polymorphism of MYH9 is associated with high systolic blood pressure in patients with CKD. The T allele in the dominant model was associated with an elevated risk for high systolic blood pressure . PMID: 27924804
24. The Raf-ERK1/2 signaling pathway is involved in regulation of NMIIA by DT-13. PMID: 27374701
25. The tumor microenvironment can regulate NMIIA in cancer cells. PMID: 27350172
26. HhnRNP-K-mediated regulation of NMHC IIA mRNA translation contributes to the control of enucleation in erythropoiesis. PMID: 26823606
27. Data show that a heterozygous missense mutation c.4270G>A (p.Aspl841Asn) in exon 30 of the non-muscle myosin heavy chain 9 (MYH9) gene was identified in all affected members from thE family. PMID: 27577209
28. the present study indicated that knockdown of NMIIA inhibited the migration and invasion of gastric cancer cells, which may be, at least in part, mediated via the JNK signaling pathway. PMID: 26719067
29. Knocking down myosin-9 or promoting protein S-glutathionylation by knocking down glutaredoxin-1 inhibited the death of airway smooth muscle cells by heating to simulate bronchial thermoplasty PMID: 26499037
30. Severity and progression of sensorineural hearing loss appeared to depend on the specific NMMHC-IIA mutation in patients with MYH9-related disease. PMID: 26226608
31. 7 members in 3 generations of a family had macrothrombocytopenia without Alport syndrome, and they all had a p.A95V mutation in exon 1 of MYH9. This affects the motor domain. PMID: 26861218
32. heterozygotic form (allele A) of the MYH9 gene could be considered a very early marker, a new risk factor for the appearance of CKD, or a sign of renal frailty in elderly people. PMID: 26152646
33. concordant with the genetic interaction observed in sickle cell disease patients, APOL1 G2 reduces myh9 expression in vivo, suggesting a possible interaction between the altered APOL1 and myh9. PMID: 26147622
34. myosin IIA and IIB heavy chains play distinct and non-redundant roles in matrix remodeling PMID: 26136073
35. Inhibition of NMMHC IIA impedes TF expression and venous thrombosis via Akt/GSK3beta-NF-kappaB signalling pathways in the endothelium both in vitro and in vivo. PMID: 25881103
36. revealed that MYH9 is expressed in a subset of NSCLC with a more malignant nature, and its expression is an indicator of a poorer survival probability PMID: 25826333
37. R705H mutation of MYH9 is associated with MYH9-related disease characterized by hearing impairment, thrombocytopenia, giant platelets, leukocyte inclusions, and mild to moderate elevation of some liver enzymes PMID: 24890873
38. Data show that myosin II supports a stable Rho zone at the at E-cadherin junctions. PMID: 26368311
39. MYH9 gene polymorphisms may be associated with multiple cerebrovascular blood flow phenotypes in Chinese patients with type 2 diabetes PMID: 25730040
40. High myosin-9 expression is associated with esophageal squamous cell carcinoma. PMID: 25605255
41. One complicating factor in this case is the diagnosis of MYH9RD in this patient. PMID: 25424224
42. A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia. PMID: 26051904
43. MYH9 p.R1165C mutation is associated with MYH9 Disorder. PMID: 26056797
44. we tested the effect of loss of MYH9 expression in podocytes in vitro, and found that it was necessary for cytoskeletal organization PMID: 24949636
45. Whereas most nonmuscle myosin IIA (MIIA) at the leading edge assembled into dorsal contractile arcs, a substantial subset assembled in or was captured within maturing focal adhesions, and this behavior was promoted by active Rac1. PMID: 25544611
46. the role of myosin IIA and its specific kinase, myosin light chain kinase, during Shigella intercellular spreading was investigated in HeLa cells PMID: 24989342
47. A novel mechanism of regulation of NMHC-IIA activity relying on the phosphorylation of Tyr-158 by Src. PMID: 25635050
48. These findings indicate that overexpression of NMIIA may contribute to the progression and poor prognosis of GC. PMID: 23203126
49. Matrix stiffness couples to myosin-II activity to promote lamin-A,C dephosphorylation at Ser22, which regulates turnover, lamina physical properties, and actomyosin expression. Lamin-A,C phosphorylation is low in interphase versus dividing cells. PMID: 25127216
50. The role of myosin II in shape control of invasive cells migrating in 3D collagen gels, was studied. PMID: 25621949
顯示更多

收起更多
相關疾?。?/div>
May-Hegglin anomaly (MHA); Sebastian syndrome (SBS); Fechtner syndrome (FTNS); Epstein syndrome (EPSTNS); Deafness, autosomal dominant, 17 (DFNA17); Macrothrombocytopenia and progressive sensorineural deafness (MPSD)
亞細胞定位：

Cytoplasm, cytoskeleton. Cytoplasm, cell cortex. Cytoplasmic vesicle, secretory vesicle, Cortical granule.
蛋白家族：

TRAFAC class myosin-kinesin ATPase superfamily, Myosin family
組織特異性：

In the kidney, expressed in the glomeruli. Also expressed in leukocytes.
數據庫鏈接：

HGNC: 7579

OMIM: 153640

KEGG: hsa:4627

STRING: 9606.ENSP00000216181

UniGene: Hs.474751